Premium
Treatment of Lithium‐Induced Diabetes Insipidus with Amiloride
Author(s) -
Finch Christopher K.,
Kelley Kristi W.,
Williams Raela B.
Publication year - 2003
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.23.4.546.32121
Subject(s) - nephrogenic diabetes insipidus , polyuria , diabetes insipidus , amiloride , lithium (medication) , medicine , thiazide , urine osmolality , endocrinology , lithium carbonate , aquaporin 2 , antipsychotic , polydipsia , diuretic , schizophrenia (object oriented programming) , diabetes mellitus , sodium , vasopressin , chemistry , psychiatry , ion , water channel , mechanical engineering , organic chemistry , ionic bonding , engineering , inlet
A 63‐year‐old African‐American woman was admitted to the hospital with urosepsis and altered mental status. She had a history of schizophrenia and was treated with olanzapine 5 mg/day and lithium carbonate 300 mg 3 times/day. During her hospital stay, her sodium level and serum osmolality increased and her urine osmolality decreased, whereas her lithium levels remained within normal limits. Based on these findings, the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride. Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium‐induced polyuria and nephrogenic diabetes insipidus. Recently, amiloride, a potassium‐sparing diuretic, has been reported as a successful treatment for nephrogenic diabetes insipidus.